Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Regarding non-pharmacological treatments, most common prescriptions were oxygen therapies and flu and pneumococcal vaccination (16.2%), and no difference in prescription pattern was observed between groups (Table 4).Prescribed treatments for IPF management (including comorbidities) at 12 months according to baseline predicted FVC%Prescribed treatmentsTotalFVC < 50%FVC 50 to 80%FVC > 80%P valueTotal number of pharmacological treatments, n (%)†344 (100.0%)53 (100.0%)252 (100.0%)39 (100.0%) < 0.0001 Antifibrotica201 (58.4%)14 (26.4%)160 (63.5%)27 (69.2%) Antacidsb65 (18.9%)5 (9.4%)54 (21.4%)6 (15.4%) Systemic corticosteroidsc23 (6.7%)8 (15.1%)15 (6.0%)0 (0.0%) Antibiotics for systemic used15 (4.4%)9 (17.0%)4 (1.6%)2 (5.1%) Mucolyticse2 (0.6%)0 (0.0%)2 (0.8%)0 (0.0%) Anticoagulantsf2 (0.6%)1 (1.9%)1 (0.4%)0 (0.0%) Otherg36 (10.5%)16 (30.2%)16 (6.3%)4 (10.3%)Total number of non-pharmacological treatments, n (%)‡74 (100.0%)27 (100.0%)43 (100.0%)4 (100.0%)0.6688 Liquid oxygen therapy13 (17.6%)5 (18.5%)7 (16.3%)1 (25.0%) Electric portable oxygen therapy14 (18.9%)5 (18.5%)9 (20.9%)0 (0.0%) Oxygen therapy with oxygen concentrator16 (21.6%)6 (22.2%)9 (20.9%)1 (25.0%) Oxygen therapy portable device12 (16.2%)2 (7.4%)8 (18.6%)2 (50.0%) NIMV3 (4.1%)2 (7.4%)1 (2.3%)0 (0.0%) Flu and pneumococcal vaccination12 (16.2%)4 (14.8%)8 (18.6%)0 (0.0%) Nutritional supplements2 (2.7%)2 (7.4%)0 (0.0%)0 (0.0%) Otherh2 (2.7%)1 (3.7%)1 (2.3%)0 (0.0%)FVC forced vital capacity, ICU intensive care unit, IPF idiopathic pulmonary fibrosis, NIMV non-invasive mechanical ventilation, SD standard deviationaIncludes nintedanib (99 prescriptions, 49.3% of all antifibrotic treatments) and pirfenidone (102 prescriptions, 50.7% of all antifibrotic treatments)bIncludes esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole and ranitidinecIncludes methylprednisolone and prednisonedIncludes azithromycin, levofloxacin, sulfamethoxazole plus trimethoprim, cefditoren, amoxicillin/clavulanic acid, ceftazidime, cefuroxime, and colistimethate sodiumeIncludes acetylcysteine and carbocisteinefIncludes dabigatran etexilate and enoxaparingIncludes antidiarrheal. anti-inflammatory /anti-infective intestinal agents, calcium. combinations with vitamin d and/or other drugs, immunosuppressants, alendronic acid, amlodipine, amphotericin B, bisoprolol, calcium carbonate, dexchlorpheniramine, dextromethorphan, fentanyl, folic acid, furosemide, indacaterol and glycopyrronium bromide, ipratropium bromide, isoniazide, loperamide in combination, metoclopramide, morphine, mycophenolic acid, tacrolimus, valganciclovir, among othershIncludes physiotherapy and other treatments†Over total number of pharmacological treatments prescribed in the total sample (n=344) and in each FVC% predicted group‡Over total number of non-pharmacological treatments prescribed in the total sample (n=74) and in each FVC% predicted group

Source: Health and non-health related resources use at 12 months. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Patients were enrolled consecutively from interstitial lung disease (ILD) units of pulmonology services where IPF is diagnosed and managed according to the Spanish health care system.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Clinical management and acute exacerbations in patients with idiopathic pulmonary fibrosis in Spain: results from the OASIS study

Study design awaiting verification · Respiratory Research · 2022

Original publication title

Clinical management and acute exacerbations in patients with idiopathic pulmonary fibrosis in Spain: results from the OASIS study

Esteban Cano-Jiménez; Ana Dolores Romero Ortiz; Ana Villar; María Jesús Rodríguez-Nieto; Alba Ramon; Silvia Armengol

© The Author(s) 2022

Original publication · Publisher record · CC BY 4.0 · CC0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

We observed a significantly higher annual IPF-related resource use in patients with more impaired lung function at baseline. Since FVC decreases irrespective of FVC% predicted at baseline, slowing IPF progression to maintain patients at early disease stages is relevant to improve IPF management and to optimize resource use.

Trial registration: EU PAS register number EUPAS19387 [June 01, 2017].

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Idiopathic pulmonary fibrosis (IPF) is a progressive disease associated with decline in lung function and poor prognosis entailing significant impairment in quality of life and high socioeconomic burden. The aim of this study was to characterize clinical management and resources utilization of patients with IPF in Spain, according to predicted forced vital capacity (FVC) % at baseline.

Source: Background

Abstract: What methods does the paper describe?

Prospective, non-interventional, multicentric real-world data study in patients with IPF in Spain with 12-months follow-up. Clinical management and resources utilization during study period were recorded and compared between groups. FVC decline and acute exacerbations occurrence and associated healthcare resource use were also analysed. FVC decline after 12 months was estimated as relative change.

Source: Methods

Abstract: Results

204 consecutive patients with IPF were included and divided according to baseline FVC % predicted value. At baseline, patients with FVC < 50% received significantly more pharmacological and non-pharmacological treatments, and more help from caregiver. During the 12-months follow-up, patients with FVC < 50% required more specialized care visits, emergency visits, hospitalizations, pulmonary functions tests, non-health resource use (special transportation), and pharmacological treatments (p < 0.05 for all comparisons). Moreover, patients with FVC < 50% at baseline experienced more AE-IPF (p < 0.05), requiring more health-related resources use (primary care visits, p < 0.05).

FVC decline was observed in all groups over the 12 months. FVC decreased on average by 2.50% (95% CI: − 5.98 to 0.98) along the year. More patients experienced an FVC decline > 10% in the more preserved lung function groups than in the FVC < 50% group, because of their already deteriorated condition.

Source: Results

Abstract: Conclusions

We observed a significantly higher annual IPF-related resource use in patients with more impaired lung function at baseline. Since FVC decreases irrespective of FVC% predicted at baseline, slowing IPF progression to maintain patients at early disease stages is relevant to improve IPF management and to optimize resource use.

Trial registration: EU PAS register number EUPAS19387 [June 01, 2017].

Source: Conclusions Source: Conclusions
Authors’ abstract

Background

Idiopathic pulmonary fibrosis (IPF) is a progressive disease associated with decline in lung function and poor prognosis entailing significant impairment in quality of life and high socioeconomic burden. The aim of this study was to characterize clinical management and resources utilization of patients with IPF in Spain, according to predicted forced vital capacity (FVC) % at baseline.

Methods

Prospective, non-interventional, multicentric real-world data study in patients with IPF in Spain with 12-months follow-up. Clinical management and resources utilization during study period were recorded and compared between groups. FVC decline and acute exacerbations occurrence and associated healthcare resource use were also analysed. FVC decline after 12 months was estimated as relative change.

Results

204 consecutive patients with IPF were included and divided according to baseline FVC % predicted value. At baseline, patients with FVC < 50% received significantly more pharmacological and non-pharmacological treatments, and more help from caregiver. During the 12-months follow-up, patients with FVC < 50% required more specialized care visits, emergency visits, hospitalizations, pulmonary functions tests, non-health resource use (special transportation), and pharmacological treatments (p < 0.05 for all comparisons). Moreover, patients with FVC < 50% at baseline experienced more AE-IPF (p < 0.05), requiring more health-related resources use (primary care visits, p < 0.05).

FVC decline was observed in all groups over the 12 months. FVC decreased on average by 2.50% (95% CI: − 5.98 to 0.98) along the year. More patients experienced an FVC decline > 10% in the more preserved lung function groups than in the FVC < 50% group, because of their already deteriorated condition.

Conclusions

We observed a significantly higher annual IPF-related resource use in patients with more impaired lung function at baseline. Since FVC decreases irrespective of FVC% predicted at baseline, slowing IPF progression to maintain patients at early disease stages is relevant to improve IPF management and to optimize resource use.

Trial registration: EU PAS register number EUPAS19387 [June 01, 2017].

Supplementary Information

The online version contains supplementary material available at 10.1186/s12931-022-02154-y.

Publication and source details

Original title: Clinical management and acute exacerbations in patients with idiopathic pulmonary fibrosis in Spain: results from the OASIS study

Esteban Cano-Jiménez; Ana Dolores Romero Ortiz; Ana Villar; María Jesús Rodríguez-Nieto; Alba Ramon; Silvia Armengol

Respiratory Research · 2022

© The Author(s) 2022https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T22:45:37.939133+00:00

DOI: 10.1186/s12931-022-02154-y · PMC9450456